U.S. Markets closed

Sigma-Aldrich, TSRI Ink Research Deal

Zacks Equity Research

Sigma-Aldrich Corporation (SIAL) has entered into a partnership with The Scripps Research Institute (TSRI) to fund research and offer publication access to TSRI researchers’ discoveries for the synthesis and analysis of potential drugs. Through this alliance, the partners promise to eliminate the delay between the invention of novel reagents and reliable, widespread applications for drug discovery.

The partnership, involving a research institute and a reagents company, is the first-of-its- kind. Following the previous partnerships with Janssen Pharmaceuticals and Bristol-Myers Squibb Company (BMY), this is TSRI’s third major alliance as part of the new targeted partnership strategy. Last year, Sigma-Aldrich and TSRI established a partnership to produce in bulk a toolkit of ten novel zinc-based salts discovered in the Baran lab.

According to the present deal, Sigma-Aldrich will fund developments of novel reagents from six TSRI research labs led by eminent professors including Nobel Laureate K. Barry Sharpless. The discoveries of the synthesis and analysis of potential drugs by the TSRI chemists and scientists will be immediately published by Sigma-Aldrich via a master licensing agreement.

TSRI will be utilizing the funds to expand its basic research capacity. This will also help chemists and scientists, who do not have a background in chemical synthesis, to now have unrestrained access to new reagents for the translational research community and implement novel reagents in their research.

The partnership will also bring an end to the hurdles faced by the researchers to get the novel reagents inventions receive reliable and widespread access to those reagents for the translational research community. Thus, the initiative taken by TSRI will open a myriad of novel technologies.   

Sigma-Aldrich expects the partnership with TSRI to reinforce its strategy of broadening the research portfolio of innovative products and tools used by the translational research community.

Headquartered in La Jolla, Calif., TSRI is a non-profit , independent American medical research organization that focuses on research and education in the biomedical sciences. TSRI is famous for its remarkable contributions to science and health, including its role in laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases.

Sigma-Aldrich, which is a prominent player in the specialty chemical space along with American Vanguard Corp. (AVD) and Ferro Corp. (FOE), is a Life Science and High Technology company whose biochemical, organic chemical products, kits and services are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical, diagnostics and high technology manufacturing.

Sigma-Aldrich currently maintains a Zacks Rank #4 (Sell).

Read the Full Research Report on SIAL

Read the Full Research Report on BMY

Read the Full Research Report on FOE

Read the Full Research Report on AVD

Zacks Investment Research

More From Zacks.com